NCT02557971 - Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder | Biotech Hunter

Enrollment

315

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions

Urinary Bladder, Overactive

Interventions

DRUG

onabotulinumtoxinA

OnabotulinumtoxinA (BOTOX®) as prescribed in clinical practice.

Trial Locations (7)

Virginia Women's Center Inc., Richmond

Forsyth Memorial Hospital Inc. dba Novant Health Urology Partners, Winston-Salem

Alliance Urology Specialists, PA, Greensboro

The Charlotte-Mecklenburg Hospital Authority DBA Carolinas Healthcare System, Charlotte

MetroHealth Medical Center, Cleveland

Capital Region Urology, Irvine

University of California, Davis, Davis